Dr. Katz is the founding (1998) director of Yale University’s Yale-Griffin Prevention Research Center, a CDC-funded clinical research lab he has run for 20 years. He has secured and managed over $40 million in total research funding, from the CDC (primary funding source); the NIH; other federal agencies; non-profit foundations; and industry. He has overseen dozens of community and clinical intervention trials, and generated roughly 200 peer-reviewed publications.
Research conducted by Dr. Katz and his colleagues developed and validated the world’s most sophisticated nutrient profiling algorithm (https://www.ncbi.nlm.nih.gov/pubmed/19928486 ; https://www.ncbi.nlm.nih.gov/pubmed/20181809 ; https://www.ncbi.nlm.nih.gov/pubmed/21496749);
Developed the concept of food label literacy and validated the world’s first dedicated instrument for its assessment (https://www.ncbi.nlm.nih.gov/pubmed/21158862; https://www.ncbi.nlm.nih.gov/pubmed/22406011);
Demonstrated the value of brief activity bursts throughout the school day (https://www.ncbi.nlm.nih.gov/pubmed/20550840 );
Introduced a method of evidence assessment called “evidence mapping” (https://www.ncbi.nlm.nih.gov/pubmed/12868249) subsequently adopted by the World Health Organization (https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/1471-2288-11-92) and now routinely cited in the peer-reviewed literature (https://academic.oup.com/ajcn/article/98/3/755/4577157);
Demonstrated the utility of massage therapy for osteoarthritis (https://www.ncbi.nlm.nih.gov/pubmed/17159021);
Developed a novel research method for community-based participatory research at multiple sites (https://www.ncbi.nlm.nih.gov/pubmed/21680935); and helped to establish the not-for-profit Advancing Health after Hysterectomy initiative (https://www.ncbi.nlm.nih.gov/pubmed/23865654).
Current (2018) research projects include the validation of a fundamental innovation in dietary intake assessment (https://www.dqpn.io/) and the development of a new method for applying hierarchies of evidence to lifestyle medicine called “evidence pathway threshold mapping.”